Edgewise to Sell Muscular Dystrophy Unit in $2.65B Deal

Dow Jones

Jun 01

By Katherine Hamilton

Edgewise Therapeutics agreed to sell sevasemten and its muscular dystrophy business for up to $2.65 billion.

The biopharmaceutical company said Monday it would sell the business to Servier, an independent pharmaceutical group run by a foundation.

Servier will pay $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, Edgewise said.

Following the deal, Edgewise will focus on cardiovascular treatments.

All Edgewise employees who primarily work in muscular dystrophy will receive a comparable offer at Servier.

Edgewise shares gained 28% to $42.86 in pre-market trading Monday.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

June 01, 2026 08:55 ET (12:55 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2640954631"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640954631\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640954631?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640954631","market":"nz","top_or_hot":-1,"title":"Edgewise to Sell Muscular Dystrophy Unit in $2.65B Deal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> agreed to sell sevasemten and its muscular dystrophy business for up to $2.65 billion. \n</p>\n<p>\n  The biopharmaceutical company said Monday it would sell the business to Servier, an independent pharmaceutical group run by a foundation. \n</p>\n<p>\n  Servier will pay $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, Edgewise said. \n</p>\n<p>\n  Following the deal, Edgewise will focus on cardiovascular treatments. \n</p>\n<p>\n  All Edgewise employees who primarily work in muscular dystrophy will receive a comparable offer at Servier. \n</p>\n<p>\n  Edgewise shares gained 28% to $42.86 in pre-market trading Monday. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 08:55 ET (12:55 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise to Sell Muscular Dystrophy Unit in $2.65B Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise to Sell Muscular Dystrophy Unit in $2.65B Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-01 20:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> agreed to sell sevasemten and its muscular dystrophy business for up to $2.65 billion. \n</p>\n<p>\n  The biopharmaceutical company said Monday it would sell the business to Servier, an independent pharmaceutical group run by a foundation. \n</p>\n<p>\n  Servier will pay $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, Edgewise said. \n</p>\n<p>\n  Following the deal, Edgewise will focus on cardiovascular treatments. \n</p>\n<p>\n  All Edgewise employees who primarily work in muscular dystrophy will receive a comparable offer at Servier. \n</p>\n<p>\n  Edgewise shares gained 28% to $42.86 in pre-market trading Monday. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 08:55 ET (12:55 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EWTX","symbol_name":"Edgewise Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640954631","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640954631","pubTimestamp":1780318500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Edgewise Therapeutics agreed to sell sevasemten and its muscular dystrophy business for up to $2.65 billion.The biopharmaceutical company said Monday it would sell the business to Servier, an independent pharmaceutical group run by a foundation.Servier will pay $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, Edgewise said.Following the deal, Edgewise will focus on cardiovascular treatments.All Edgewise employees who primarily work in muscular dystrophy will receive a comparable offer at Servier.Edgewise shares gained 28% to $42.86 in pre-market trading Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EWTX":"Edgewise Therapeutics, Inc.","BK4007":"制药","BK4539":"次新股"},"translate_title":"Edgewise将以$2.65 B的价格出售肌肉萎缩症部门","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Edgewise Therapeutics agreed to sell sevasemten and its muscular dystrophy business for up to $2.65 billion. \n\n\n  The biopharmaceutical company said Monday it would sell the business to Servier, an independent pharmaceutical group run by a foundation. \n\n\n  Servier will pay $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, Edgewise said. \n\n\n  Following the deal, Edgewise will focus on cardiovascular treatments. \n\n\n  All Edgewise employees who primarily work in muscular dystrophy will receive a comparable offer at Servier. \n\n\n  Edgewise shares gained 28% to $42.86 in pre-market trading Monday. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 08:55 ET (12:55 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}